NCT02933034View on ClinicalTrials.gov

Clinical Trial of Manganese-Enhanced MRI (MEMRI) to Assess Peri-Infarct Injury

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

33

Participants

Timeline

Start Date

April 30, 2015

Primary Completion Date

February 3, 2019

Study Completion Date

February 3, 2019

Conditions
ISCHEMIC CARDIOMYOPATHY
Interventions
DRUG

Manganese-enhanced MRI contrast reagent

MRI using manganese-enhanced MRI contrast reagent (manganese 0.28 mL/kg).

DRUG

Gadolinium-enhanced MRI contrast reagent

MRI using gadolinium-enhanced MRI contrast reagent (gadolinium 0.2 mmol/kg).

Trial Locations (1)

94305

Stanford University School of Medicine, Stanford

All Listed Sponsors
collaborator

General Electric

INDUSTRY

lead

Stanford University

OTHER

NCT02933034 - Clinical Trial of Manganese-Enhanced MRI (MEMRI) to Assess Peri-Infarct Injury | Biotech Hunter | Biotech Hunter